Rinvoq vs Stelara for Crohn's: Oral JAK or Biologic

If your gastroenterologist has put Rinvoq vs Stelara in front of you, the first thing worth knowing is that these two drugs have never been tested against each other in a randomised Crohn's disease trial. Every percentage you will read comparing them comes from separate studies, run years apart, in differently chosen patients. That clears the ground: once you stop looking for a winner, you can compare what genuinely lines up.

Key Takeaways

• Rinvoq vs Stelara has never been settled by a head-to-head randomised trial in Crohn's, so no percentage from upadacitinib's trials beats one from ustekinumab's
• Rinvoq is one tablet a day: 45 mg for 12 weeks, then 15 mg daily, with 30 mg an option in severe or extensive disease (3)
• Stelara is a single weight-based infusion, then 90 mg injected at week 8 and every 8 weeks after, about six maintenance doses a year (4)
• Rinvoq carries an FDA boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Stelara's label has no boxed warning (3, 4)
• The two programmes measured different things: Rinvoq's induction endpoint was clinical remission at week 12, Stelara's was clinical response at week 6 (1, 2)
• The boxed warning matters most if you are older, smoke, or have a history of heart disease, clots or cancer. Otherwise the practical differences decide it

Rinvoq vs Stelara: Two Drugs That Switch Off Inflammation in Different Places

Rinvoq and Stelara both reduce Crohn's inflammation, but on opposite sides of the cell membrane. Rinvoq (upadacitinib) is a small molecule you swallow, a selective Janus kinase inhibitor that blocks signalling inside immune cells. Stelara (ustekinumab) is a large antibody that must be injected, and it works outside the cell.

Janus kinases, usually shortened to JAKs, are enzymes just inside the cell wall that relay inflammatory signals into the nucleus. Blocking them turns down many pathways at once, and because upadacitinib is a small molecule it survives digestion and can be a tablet. Our Rinvoq (upadacitinib) patient guide covers the drug alone.

Ustekinumab is a monoclonal antibody, a lab-made protein built to recognise one target: the p40 subunit shared by interleukin-12 and interleukin-23. Binding p40 blocks both messengers before they reach a cell (4). Antibodies are destroyed by stomach acid, which is why Stelara must be infused or injected. Our Stelara (ustekinumab) patient guide goes deeper.

Both are labelled for moderately to severely active Crohn's, but Rinvoq's FDA indication is specifically for adults with an inadequate response to or intolerance of one or more TNF blockers (3), so many of us only reach this comparison after infliximab or adalimumab has stopped working.

What Each Drug's Trials Showed, and Why You Cannot Line Them Up

Rinvoq and Stelara have never been compared directly in a randomised Crohn's trial. Everything online comparing them comes from separate placebo-controlled trials run years apart, or from network meta-analyses stitching those trials together. Neither is a head-to-head result.

No head-to-head trial exists, and that matters

The 2026 Cochrane network meta-analysis of Crohn's treatments pooled 94 studies and 27,476 participants, and its authors still concluded that head-to-head trials of specific agents may be needed (5). When the largest synthesis available says the direct evidence is missing, be sceptical of any article implying a winner.

Rinvoq: U-EXCEL, U-EXCEED and U-ENDURE

Research published in the New England Journal of Medicine reported two induction trials and one maintenance trial. With 45 mg once daily, clinical remission at week 12 was 49.5% versus 29.1% on placebo in U-EXCEL, and 38.9% versus 21.1% in U-EXCEED, which enrolled patients who had already failed biologics (1). In U-ENDURE at week 52, remission was 37.3% on 15 mg and 47.6% on 30 mg, against 15.1% on placebo (1).

Stelara: UNITI-1, UNITI-2 and IM-UNITI

The ustekinumab programme appeared in the same journal in 2016. In UNITI-1, where every patient had already failed TNF antagonists, clinical response at week 6 was 34.3% and 33.7% for the two doses versus 21.5% on placebo. In UNITI-2, which included less heavily treated patients, the figures were 51.7%, 55.5% and 28.7% (2). In IM-UNITI at week 44, remission was 53.1% every 8 weeks and 48.8% every 12 weeks, versus 35.9% on placebo (2).

Why the two sets of numbers are not interchangeable

Any upadacitinib vs ustekinumab comparison has to reckon with what was actually measured. Rinvoq's induction trials reported clinical remission at week 12. The UNITI induction trials reported clinical response at week 6. Those are different thresholds at different moments, so putting 49.5% next to 51.7% compares two different things.

The populations differ too, in the same direction in both programmes. U-EXCEED and UNITI-1 enrolled patients who had already failed biologics, and remission and response rates were consistently lower in those groups than in U-EXCEL and UNITI-2. Your treatment history matters more than any headline figure.

A Daily Pill or an Infusion Then Injections

Here the drugs genuinely can be compared, because the schedules are on the labels. Rinvoq is one extended-release tablet once daily, 45 mg for 12 weeks of induction, then 15 mg daily for maintenance, with 30 mg daily an option for refractory, severe or extensive disease (3). Stelara starts with a single weight-based infusion of 260 mg, 390 mg or 520 mg, then 90 mg subcutaneously at week 8 and every 8 weeks after (4).

Day to day that is a real difference in texture. With Rinvoq there are no needles and no infusion appointments, but something to remember every morning. With Stelara there is one clinic visit, then roughly six injections a year.

The logistics cut both ways. A tablet travels easily and needs no refrigeration, but a missed dose can happen on a bad week. A refrigerated injectable needs storage planning around travel, but six doses a year is six decisions a year.

Speed of onset, stated carefully

The Rinvoq label reports onset of clinical response based on CDAI as early as two weeks in both Crohn's induction studies (3). Stelara's induction endpoint was measured at week 6 (2). That is a difference in how each was studied, not proof one acts faster, because nobody measured them side by side. If getting out of a bad flare quickly matters to you, it is still worth raising.

The Safety Difference Is the Biggest Real Gap

If one thing separates these drugs cleanly, it is the labels. Rinvoq carries an FDA boxed warning, the strongest warning the agency applies, covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis (3). Stelara's prescribing information has no boxed warning (4). That gap is not a technicality, and it often tips the decision.

Rinvoq's boxed warning in plain language

The warning covers five things: serious infections, including tuberculosis and opportunistic infections that can lead to hospitalisation or death; mortality, meaning a higher rate of death from any cause; malignancy, including lymphoma and skin cancers; major adverse cardiovascular events, or MACE, meaning heart attack, stroke and cardiovascular death; and thrombosis, meaning clots in veins, lungs and arteries (3).

Where those findings came from matters. The mortality, malignancy and MACE bullets reference a different JAK inhibitor compared against TNF blockers in rheumatoid arthritis patients, not the Crohn's trials (3), which is why the warning applies to the JAK class as a whole. That does not make the risk imaginary, but it was not measured in Crohn's.

Monitoring is part of the deal. Latent tuberculosis testing is required before starting Rinvoq, latent TB must be treated first, and monitoring for active TB continues even after a negative test (3). Adverse reactions in at least 5% of Crohn's patients were upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster and headache (3). Our article on what side effects Rinvoq patients actually report covers the lived experience.

What Stelara's label warns about instead

No boxed warning does not mean no warnings. Stelara's Warnings and Precautions cover infections, pre-treatment tuberculosis evaluation, malignancies, hypersensitivity reactions, posterior reversible encephalopathy syndrome and noninfectious pneumonia (4).

Taken together, the boxed warning matters most for a specific group: older patients, current or past smokers, and anyone with a history of cardiovascular disease, clots or malignancy. These are exactly the people whose gastroenterologist is likely to lean toward the biologic, so say so rather than waiting to be asked.

Cost, Coverage and Getting Approved

On Stelara vs Rinvoq cost, your insurance decides far more than the list price does. Both are specialty medications that almost always require prior authorisation, and most plans require documented failure of or intolerance to a TNF blocker before Rinvoq, matching its label (3). Everything below is US-specific.

AbbVie's Rinvoq Complete programme states that eligible commercially insured patients could pay $0 a month, with restrictions and monthly maximums, and that the card is unavailable to anyone covered by Medicare including Part D, Medicare Advantage or Medigap, or by Medicaid, TRICARE, the Department of Defense or Veterans Affairs programmes (6). Checked 2026-10-06.

Janssen's STELARA withMe Savings Program states that eligible commercially insured patients aged 6 and older pay $5 per dose with no income requirement, that a maximum program benefit applies per calendar year, and that it excludes anyone on a state or federal government-funded programme such as Medicare, Medicaid, TRICARE, the Department of Defense or the Veterans Administration (7). Checked 2026-10-06.

On Medicare neither copay card is available. The number that matters instead is the Part D annual out-of-pocket cap, $2,100 in 2026, which includes the deductible and out-of-pocket spending but not premiums (8). Checked 2026-10-06.

One wrinkle rarely gets named: benefit design. An oral tablet runs through your pharmacy benefit, while Stelara's starting infusion is typically billed as a medical benefit, so the paperwork and the bills arrive through different doors. Ustekinumab biosimilars have also changed Stelara's cost picture, which can affect which drug a plan prefers. Our Stelara cost and biosimilars guide has the detail.

How the Choice Actually Gets Made

In clinic the JAK inhibitor vs biologic decision rarely turns on efficacy numbers. It turns on your risk profile, your tolerance for needles or daily pills, and what your plan will approve.

Factors that tend to favour Stelara: cardiovascular risk, a history of clots or cancer, older age, pregnancy planning, a preference for something taken six times a year, or a plan that prefers a biosimilar.

Factors that tend to favour Rinvoq: needle aversion, no reliable infusion access, a wish to avoid injections entirely, prior failure of an IL-12/23 or IL-23 biologic, or wanting a drug whose label documents a response within weeks.

Both are reasonable next steps after a TNF blocker fails, and in our community plenty of people have tried both. Starting one does not close the door on the other.

Questions worth asking at the appointment

• Where does each sit on my plan's formulary, and which can I start soonest?
• Given my age, smoking history and cardiovascular and cancer risk, does the boxed warning change your pick?
• What monitoring will I need, and how often will I be in for bloods?
• How long will we give this before we call it a failure?
• If I start the tablet, what happens if I miss doses during a bad week?

Rinvoq vs Stelara is not a contest with a winner hiding in the data. It is a matching exercise between two genuinely different drugs, and the strongest inputs are your own risk factors and your own life. Make this decision with a gastroenterologist who knows your disease location, history and risk factors, not from an article.

Frequently Asked Questions

Is Rinvoq or Stelara better for Crohn's disease?

Neither can be called better, because no head-to-head randomised trial has compared them in Crohn's. Their programmes measured different endpoints at different times in differently selected patients (1, 2), and the 2026 Cochrane network meta-analysis of 94 studies still called for head-to-head trials (5). The honest comparison is on route, schedule, safety and coverage.

Why does Rinvoq have a boxed warning when Stelara does not?

Rinvoq's boxed warning covers serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis (3). The mortality, malignancy and MACE findings come from a different JAK inhibitor studied against TNF blockers in rheumatoid arthritis patients, so the warning applies to the JAK class rather than arising from the Crohn's trials (3). Stelara is an antibody, not a JAK inhibitor, and carries no boxed warning (4).

Can I switch from Stelara to Rinvoq, or the other way round?

Switching is routine when a drug stops controlling the disease, and because these two act on completely different targets, one can work after the other has failed. Prior failure of an IL-12/23 biologic is one situation where a JAK inhibitor is often considered next.

Do I need to have failed a TNF blocker first?

For Rinvoq, usually yes. Its FDA indication is for adults with an inadequate response to or intolerance of one or more TNF blockers (3), and most US plans require documented failure first. Stelara's positioning varies more by plan and country, so ask your clinic what your formulary requires.

Is Rinvoq or Stelara cheaper?

That depends on your insurance, not on list prices. For eligible commercially insured US patients, AbbVie states Rinvoq Complete could mean $0 a month with restrictions and monthly maximums (6), and Janssen states STELARA withMe means $5 per dose with an annual maximum benefit (7). Both exclude government-insured patients. On Medicare the 2026 Part D out-of-pocket cap is $2,100 (8). Checked 2026-10-06.

References

1. Loftus EV, et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2023. View on PubMed
2. Feagan BG, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2016. View on PubMed
3. AbbVie. RINVOQ (upadacitinib) US Prescribing Information. 2026. Read label
4. Janssen Biotech. STELARA (ustekinumab) US Prescribing Information. 2026. Read label
5. Cochrane. Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. 2026. Read review
6. AbbVie. RINVOQ Complete Savings Card and cost information. 2026. Read article
7. Janssen Biotech. STELARA withMe Savings Program Overview. 2026. Read article
8. Medicare.gov. Medicare costs. 2026. Read article